About AngioInsight
AngioInsight makes software for heart doctors that examines routine images of the heart’s arteries. It is designed to find narrowed vessels and blood-flow problems in both large arteries and tiny vessels. Its AngioAI+ platform analyzes images shortly after capture and uses standard angiography without extra hardware. The automated workflow is intended to avoid specialist operators.
AngioInsight is based in Minnetonka, Minnesota. Scott Burger is chief executive officer. Before this role, he was chief commercial officer at Elucid and CorVista Health. Alberto Figueroa is co-founder and chief science officer. He holds a Stanford doctorate in biomechanical engineering.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 9, 2025 | Nov 10, 2026 | $16,314,000of $20.0M target | 94 | $173K | OptionsRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by AngioInsight
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Oct 23, 2025 | Series A | $25 million target | Company announcement ↗ |
Why Investors Backed AngioInsight
AngioInsight develops software that helps cardiologists analyze coronary angiograms. AngioInsight’s view is that one routine image workflow can assess both major arteries and tiny vessels. AngioAI+ remains investigational and has not received FDA clearance.
The problem it targets
Coronary microvascular disease can cause chest pain even when major arteries show no blockages. Its symptoms overlap with other heart conditions, and routine angiography can miss problems in tiny vessels. Current detection may require invasive wires. Some noninvasive tests are costly, unavailable, or use radiation. Women account for more than half of cases. AngioInsight is targeting this diagnostic gap.
What the product does
AngioAI+ analyzes routine coronary angiography video soon after capture. SMARTFLOW will assess its estimates of fractional flow reserve and its detection of coronary microvascular disease. The study will also evaluate three-dimensional vessel reconstruction and stenosis assessment. The system uses software alone, without additional invasive instruments or workflow changes. It is intended to produce diagnostic information within minutes.
Progress so far
On August 5, 2026, AngioInsight announced that SMARTFLOW had enrolled its first patient at Minneapolis Heart Institute Foundation within Abbott Northwestern Hospital. The prospective multicenter study expects about 600 patients across 17 cardiovascular centers in the United States and Europe. Carlos Collet and Todd Villines are co-principal investigators. The program will compare results with established invasive standards and involves the Cardiovascular Research Foundation. AngioInsight plans to use the evidence for future regulatory filings.
Who backs it
After closing an oversubscribed seed round, AngioInsight opened another financing round for clinical evaluation and a commercial launch. Shlomi Nachman joined the board at the same time. He previously chaired Johnson & Johnson’s cardiovascular and specialty solutions group. In that role, he oversaw $9 billion in annual revenue.
How the market is moving
Coronary artery disease affects more than 20.5 million U.S. adults and remains the most common form of heart disease. More than 2.2 million affected patients undergo angiography each year. Nearly 2 million receive diagnoses based on doctors’ visual assessments of those images.
We wrote this summary from public statements by AngioInsight and its investors. It is not investment advice.
AngioInsight in the News
- SMARTFLOW Study of AngioInsight's AngioAI+ Software Platform Begins Enrollment
- AngioInsight™, Announces First Patient Enrolled in SMARTFLOW™ Clinical Study
- Medical AI startup AngioInsight adds Johnson & Johnson veteran to board while raising $25M
- AngioInsight to assess platform for cardiovascular diagnosis
Leadership Team
Executive officers and directors listed on AngioInsight's Form D filed Nov 10, 2026.
